Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-02-03 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 19 pages 182.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half year report – 31 December 2010' and references the half-year ended 31 December 2010, indicating it is an interim financial report. It includes detailed financial statements such as consolidated income statement, balance sheet, cash flows, notes, directors' report, and auditor's review report. The content includes substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but a full interim report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2011
2011-02-03 English
Appendix 3B - Grant of Employee Options 11 pages 107.5KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. The content details the issuance of unlisted employee options (Performance Rights), number of securities issued, terms of the securities, issue price, purpose of the issue, and dates related to the securities. This type of document is a capital/financing update as it relates to changes in the company's capital structure through issuance of new securities. It is not a full financial report, earnings release, or management discussion, but a formal announcement of a capital change. Therefore, the correct classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2011-01-24 English
EU Bronchitol Marketing Application Update 2 pages 83.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 25 January 2011 from Pharmaxis Ltd regarding an update on the EU marketing authorization process for their product Bronchitol for cystic fibrosis. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings information, and no detailed financial or operational report. It is a public announcement about regulatory progress and clinical trial status, typical of a press release or media update. The document length is under 5,000 characters and it does not contain or attach any formal report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement and compliance update that does not fit other specific categories.
2011-01-24 English
Appendix 4C - quarterly 5 pages 117.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements for the quarter ended 31 December 2010. It includes operating, investing, and financing cash flows, reconciliation of cash, and compliance statements. The document is approximately 13,819 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report providing actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2010
2011-01-24 English
Quarterly Report to Shareholders 8 pages 440.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report to Shareholders' and covers the period October to December 2010, indicating it is a quarterly report. It contains detailed information about the company's business, product development, clinical trials, regulatory status, and future outlook. The content includes substantive financial and operational data, clinical trial results, regulatory updates, and management commentary. The length is about 15,000 characters, which is consistent with a comprehensive interim or quarterly report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2010
2011-01-24 English
Quarterly Investor Report and Conference Call 1 pag
Call Transcript Classification · 90% confidence The document is a media release announcing an upcoming quarterly report release and an investor teleconference (conference call) to discuss the quarter. It does not contain the actual quarterly financial report or substantive financial data, but rather informs about the timing of the report release and the call. The presence of teleconference details and mention of a recording indicates this is a Call Transcript announcement or invitation. Since the actual transcript is not included, and the document is short (1246 characters), it is best classified as a Call Transcript (CT) type, as it relates directly to the conference call event. Confidence is high due to clear mention of the quarterly report release and conference call details.
2011-01-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.